Ahmad Tarhini1, Christopher Atzinger2, Komal Gupte-Singh3, Courtney Johnson2, Cynthia Macahilig4, Sumati Rao3. 1. Department of Hematology & Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH 441062, USA. 2. Pharmerit International, Bethesda, MD 208143, USA. 3. Bristol-Myers Squibb, Princeton, NJ 086484, USA. 4. Medical Data Analytics, Parsippany, NJ 07054, USA.
Abstract
Aim: To describe treatment patterns and outcomes of patients with unresectable stage III and metastatic/stage IV melanoma. Materials & methods: An observational retrospective chart review of patients diagnosed with advanced melanoma before 1 November 2015 who initiated a new line of therapy (LOT) from 1 January 2015 to 31 May 2016. Results: Among 487 patients, ipilimumab monotherapy (27.5%) was the most common first line of therapy (1LOT) in 2015, surpassed by nivolumab monotherapy (21.5%) in 2016. 12-month survival was ≥80.1%; proportions were highest forpatients treated with nivolumab + ipilimumab (86.6%). All treatments relatively well tolerated in real-world setting and adverse events were consistent with the previously reported safety profiles. Conclusion: This study provides important insights into real-world advanced melanoma treatment patterns and demonstrates encouraging treatment safety and patient survival data.
Aim: To describe treatment patterns and outcomes of patients with unresectable stage III and metastatic/stage IV melanoma. Materials & methods: An observational retrospective chart review of patients diagnosed with advanced melanoma before 1 November 2015 who initiated a new line of therapy (LOT) from 1 January 2015 to 31 May 2016. Results: Among 487 patients, ipilimumab monotherapy (27.5%) was the most common first line of therapy (1LOT) in 2015, surpassed by nivolumab monotherapy (21.5%) in 2016. 12-month survival was ≥80.1%; proportions were highest forpatients treated with nivolumab + ipilimumab (86.6%). All treatments relatively well tolerated in real-world setting and adverse events were consistent with the previously reported safety profiles. Conclusion: This study provides important insights into real-world advanced melanoma treatment patterns and demonstrates encouraging treatment safety and patient survival data.
Entities:
Keywords:
advanced melanoma; immunotherapy; ipilimumab; line of therapy; metastatic melanoma; nivolumab; overall survival; progression-free survival; treatment patterns
Authors: Arthur L Burnett; David R Walker; Qi Feng; Karissa M Johnston; Greta Lozano-Ortega; David Nimke; John C Hairston Journal: Neurourol Urodyn Date: 2020-05-08 Impact factor: 2.696
Authors: Ahmad A Tarhini; Sandra J Lee; Aik-Choon Tan; Issam M El Naqa; F Stephen Hodi; Lisa H Butterfield; William A LaFramboise; Walter J Storkus; Arivarasan D Karunamurthy; Jose R Conejo-Garcia; Patrick Hwu; Howard Streicher; Vernon K Sondak; John M Kirkwood Journal: J Immunother Cancer Date: 2022-01 Impact factor: 12.469
Authors: Ahmad A Tarhini; Sandra J Lee; F Stephen Hodi; Uma N M Rao; Gary I Cohen; Omid Hamid; Laura F Hutchins; Jeffrey A Sosman; Harriett M Kluger; Zeynep Eroglu; Henry B Koon; Donald P Lawrence; Kari L Kendra; David R Minor; Carrie B Lee; Mark R Albertini; Lawrence E Flaherty; Teresa M Petrella; Howard Streicher; Vernon K Sondak; John M Kirkwood Journal: J Clin Oncol Date: 2019-12-27 Impact factor: 50.717